Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
Home » Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform2019-06-262019-06-28http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.